Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Benzinga · 1d ago
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.